Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD 9.13
+0.20 (2.24%)
Jun 5, 2026, 4:10 PM AEST
Clinuvel Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Clinuvel Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $22.91. The average 1-year stock price forecast is 150.93% higher than the current stock price, while the lowest is $13.00 (+42.39%) and the highest is $39.20 (+329.35%).
Price Target: $22.91 (+150.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Clinuvel Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 1 | 3 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 3 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bell Potter | Bell Potter | Buy Maintains $19.00 → $17.00 | Buy | Maintains | $19.00 → $17.00 | +86.20% | May 25, 2026 |
| Jefferies | Jefferies | Buy Maintains $39.20 | Buy | Maintains | $39.20 | +329.35% | Apr 24, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $32.84 → $27.90 | Buy | Maintains | $32.84 → $27.90 | +205.59% | Mar 2, 2026 |
| Morgans | Morgans | Buy Maintains $13.00 | Buy | Maintains | $13.00 | +42.39% | Feb 27, 2026 |
| MA Financial Group | MA Financial Group | Buy Maintains $23.29 | Buy | Maintains | $23.29 | +155.09% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
99.50M
from 95.02M
Increased by 4.72%
Revenue Next Year
105.35M
from 99.50M
Increased by 5.88%
EPS This Year
0.72
from 0.72
Decreased by -0.32%
EPS Next Year
0.77
from 0.72
Increased by 6.93%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 104.8M | ||
| Avg | 99.5M | ||
| Low | 96.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.3% | ||
| Avg | 4.7% | ||
| Low | 1.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 0.72 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -0.3% | ||
| Low | - |